CHOLESTASIS AND LIVER DISEASE
RESOLVED
DISCOVER
CLAUDIN-3 TARGETING
ABOUT US
CALDRE is a Switzerland based
biotech spin-out focussed to
revolutionize the way cholestatic-
and fibrotic diseases are treated.
We develop precise, liver-directed
GalNAc-siRNAs to restore bile flow
and prevent fibrosis - placing
CALDRE in the fast-growing
RNA-therapeutics segment of
biotech.
THE PROBLEM
0
US & EU patients suffering from
bile flow stagnation symptoms
10% of all liver transplants
have cholestasis as indication
0
US & EU patients with primary
sclerosing cholangitis without any
apprived treatment option
40% need a liver transplant
0
US & EU patients with
primary biliary cholangitis
in need of 2nd line treatment
500 transplants per year
OUR MISSION
Our mission is to prevent the need for liver transplantation
THE SOLUTION
ClagalsiR –Claudin-3 GalNAc-siRNA
ClagalsiR is a claudin-3 targeting, liver specific GalNAc-siRNA developed to selectively open the paracellular barrier between liver hepatocytes.
Shown in our pre-clinical in vivo models, claudin-3 inhibition increases the water content in bile - lowering bile toxicity- and thereby lowered tissue necrosis and fibrosis
THE TEAM
ADVISORS
CONSULTANTS
OUR SCIENCE
OUR SUPPORTERS & PRIZES
CALDRE joins the Kickfund portfolio
We are pleased to announce that CALDRE Ltd. has joined the portfolio of Kickfund.
